|Place Of Origin:||China (Mainland)||Brand Name:||BBCA|
|Other Names:||Pharmaceutical Grade Azithromycin Capsules||Grade:||Medicine Grade|
Pharmaceutical Grade Azithromycin Medicine Capsules BBCA Brand
Standard: 0.25g ;CP, USP, BP
Manufacture: ANHUI BBCA PHARMRACEUTICAL Co., Ltd.
Prevention and treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease due to H. influenzae, M. catarrhalis, or S. pneumoniae. The benefits of long-term prophylaxis must be weighed on a patient-by-patient basis against the risk of cardiovascular and other adverse effects.
Acute bacterial sinusitis due to H. influenzae, M. catarrhalis, or S. pneumoniae. Other agents, such as amoxicillin/clavulanate are generally preferred, however.
Community-acquired pneumonia due to C. pneumoniae, H. influenzae, M. pneumoniae, or S. pneumoniae
Acute otitis media caused by H. influenzae, M. catarrhalis or S. pneumoniae. Azithromycin is not, however, a first-line agent for this condition. Amoxicillin or another beta lactam antibiotic is generally preferred.